Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis

University of Tennessee

Status: Unknown

Conditions: Deep Venous Thrombosis

Treatments: Drug: Low-Molecular-Weight Heparin

Study type: Interventional

Funder types: Other

Identifiers

NCT01029821

Pugh-2

Details and patient eligibility

About

1. The use of LMWH following open reduction and internal fixation of ankle fractures will reduce the number of thrombi formed.
2. The rates of clinically significant DVT will be equivalent between two groups.

Full description

Routine use of thromboprophylaxis may be over treatment and definitely increases healthcare costs. While prophylaxis may reduce the number of thrombi formed the exact number and clinical significance of these is unknown. This study seeks to answer the question of whether or not DVT prophylaxis with low-molecular-weight heparin (LMWH) following ORIF of ankle fractures is warranted.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• At least 18 years old
• Surgical ankle fracture able to be definitively treated with one operation

Exclusion criteria

• Younger than 18 years of age
• Other significant injury
• Known hypercoagulable state
• History of bleeding disorder
• History of DVT

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Low-Molecular-Weight Heparin for DVT

Other group

Description:

Low-Molecular-Weight Heparin for DVT Prophylaxis after Open Reduction and Internal Fixation of ankle fractures

Treatment:

Drug: Low-Molecular-Weight Heparin